Koers Mabvax Therapeutics Holdings Inc Other OTC
Aandelen
US55414P1084
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Omzet 2016 | 148K 138K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,41 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,82 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,68 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 438K | Nettoschuld 2017 | 2,48 mln. 2,31 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+14,84% | 121 mld. | |
+18,31% | 112 mld. | |
+2,18% | 22,72 mld. | |
-18,26% | 20,82 mld. | |
-18,28% | 16,66 mld. | |
-41,55% | 16,36 mld. | |
-14,23% | 16,19 mld. | |
-0,68% | 13,17 mld. | |
+21,87% | 11,11 mld. |
- Beurs
- Aandelen
- Koers MBVXQ
- Koers